Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation

NCT01532908 is registered in ClinicalTrials.gov with MassBiologics as lead sponsor.

NCT NCT01532908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01532908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation
Lead sponsor
MassBiologics
Phase
Phase 2
Overall status
Terminated
Start date
November 21, 2012
Completion date
August 27, 2015
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c infection